BTIG raised the firm’s price target on Penumbra (PEN) to $320 from $305 and keeps a Buy rating on the shares. The company’s Q1 results topped estimates and as Penumbra moves through the remainder of FY25, comps ease notably within Thrombectomy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra’s Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Conservative FY25 Guidance
- Penumbra price target raised to $318 from $301 at Stifel
- Cautious Hold on Penumbra Despite Strong Q1 Performance and Promising Thunderbolt Prospects
- Penumbra, Inc. Reports Strong Q1 2025 Financial Growth
- Optimistic Outlook for Penumbra: Strong U.S. Thrombectomy Performance and Strategic Growth Initiatives Drive Positive Forecast